Biden Aims For 200 Million More COVID Vaccine Doses As Nervous Europe Eyes Its Borders
Executive Summary
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
You may also be interested in...
US FDA COVID Funds Move Forward In Congress, No Strings Attached
Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.
Pharma Companies May Be Asked To Help Competitors Manufacture COVID-19 Vaccines
‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’
COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.